Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (NASDAQ:LNSR), a medical technology company specializing in robotic laser systems for cataract surgery, reported earnings for the quarter ended June 30, 2025. The headline news: Revenue (GAAP) increased 10% year over year in Q2 2025, but missed analyst forecasts by a wide margin on a GAAP basis in Q2 2025. Total revenue (GAAP) was $13.9 million in Q2 2025, compared to consensus expectations of $17.1 million. Earnings per share (GAAP) also came in below estimates in Q2 2025, as the company reported a GAAP loss of ($0.15) per share in Q2 2025, compared to a consensus GAAP loss of ($0.02). Despite these misses, the Net loss (GAAP) shrank sharply from the prior year in Q2 2025, as recurring revenues and global procedure volumes reached new highs in Q2 2025. This quarter showcased operational traction in its key business line but raised questions on execution and the impact of its pending acquisition by Alcon. Source: Analyst estimates for the quarter provided by FactSet. Founded as a developer of ophthalmic laser systems, Lensar’s core business is to improve cataract surgery using advanced robotic equipment. Its main offerings include the LENSAR Laser System and the ALLY Robotic Cataract Laser System, both designed to enhance surgical precision and efficiency using imaging, robotics, and artificial intelligence (AI).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool